In this analysis, the estimated RD from each study is the risk of developing a DHPS mutation among PCP patients exposed to sulfa prophylaxis minus the risk among PCP patients not exposed to sulfa prophylaxis. The gene discussed is DHPS; the disease is pneumocystosis.